tbuckley/cabot-search huggingface dataset:
Effectiveness of tablet family history collection in a multidisciplinary pancreatic tumor clinic in identifying patients with risk factors for hereditary cancer.
Authors: Jessica Everett, Kara Schradle, Heather Cameron, Anisha Patel, Erika Koeppe, Elena Martinez Stoffel, Diane M. Simeone
Journal: Journal of Clinical Oncology (2017)

e13020 Background: A substantial percentage of patients with pancreatic adenocarcinoma (PDAC) harbor pathogenic germline variants in known cancer risk genes, some with relevance for treatment options. Robust collection of relevant personal and family cancer history risk factors for all patients with PDAC is needed to optimize identification of those who could benefit from genetic counseling and testing (GC/GT). Methods: 464 adult patients (≥18 years of age) presenting to a multi-disciplinary pancreatic tumor clinic were invited to complete a tablet based family cancer history survey prior to their clinic appointments. Standard family history entry into electronic medical record (EMR) was reviewed for comparison. Eight GC/CT referral criteria were developed based on existing guidelines for known syndromes associated with PDAC, reported findings from studies of GC/GT outcomes in patients with PDAC, and expert opinion. Presence of any of the 8 criteria were documented for both tablet and EMR collection methods in the subset of patients with PDAC (n = 230). Results: Completion rate for the tablet survey was high (87%). 78% of users completed the survey in ≤15 minutes (x̄ = 12 minutes). 202 patients with PDAC (88%) completed the tablet survey, and 100 (50%) met ≥1 GC/GT criteria. Most frequent criteria identified were: ≥2 relatives with related cancers (28%); ≥1 relative with PDAC (12.9%); personal history of related cancer (12.9%). Tablet data collection improved identification of relatives with breast cancer ca &lt; age 50 from 1.5% to 5.5% due to missing ages at diagnosis in the EMR. The tablet survey also identified 12 patients with Ashkenazi Jewish (AJ) ancestry (6%), a risk factor not accounted for in EMR. Conclusions: Tablet based family cancer history collection is well accepted by patients and easily integrated into clinic work flow. The tablet survey found GC/GT criteria in 50%, and improved identification of key risk factors for BRCA1/2 mutation (AJ ancestry, relative with breast ca &lt; age 50). Further work should focus on integration of tablet based survey data into EMR, and decision support tools to optimize referral and follow through with genetic services.
Phase II study of pazopanib in patients with von Hippel-Lindau disease.
Authors: Eric Jonasch, Dan S. Gombos, Steven G. Waguespack, Valerie Marcott, Diane D Liu, Justin Alexander Weldon, Shelly Bird, Christine Robichaux, Nizar M. Tannir, Ashley Henriksen Woodson, Greg Fuller, Ian E. McCutcheon, Surena F. Matin
Journal: Journal of Clinical Oncology (2017)

4516 Background: Von Hippel-Lindau disease (VHL) is an autosomal dominant inherited disorder. Affected individuals develop vascular neoplastic lesions in multiple sites including eye, brain, pancreas, adrenal and kidney. Standards of care include surveillance imaging and surgical intervention. We hypothesized that treatment of VHL related lesions with an antiangiogenic agent would result in shrinkage of all lesion types. We chose the multikinase inhibitor pazopanib to test this hypothesis. Methods: After obtaining IRB approval, patients with clinical features or genetic confirmation of VHL disease and with measurable lesions were treated with pazopanib 800mg PO daily for two 12-week cycles. Efficacy was determined by RECIST after two cycles. Patients had the option to continue therapy if considered in patient’s best interest. Continuous monitoring for any lesion progression and drug discontinuation due to toxicity during the whole period of the treatment was planned. Results: Patients were enrolled (N=32) and treated (N=31) between 1/2012 and 6/2016. Median age was 37 (range 19-67). 23 patients had genomically confirmed VHL disease; four had family and personal history but had not undergone genetic testing, and five patients had clinical features of VHL disease and negative genetic testing. A median of two cycles (range 1-12) of therapy was administered. Of 31 evaluable patients, 13 (42%) showed a response, 18 patients had stable disease and no patients had PD as best response. Responses were seen in renal (2 CR and 29 PR/59 total), pancreatic (9 PR/17 total) and CNS 2 PR/49 total) target lesions. The most common side effect was diarrhea (grades 1 and 2) experienced in 14 patients. Twelve patients dose reduced to 600 mg and 6 to 400 mg pazopanib PO daily. Eight patients discontinued therapy due to adverse events of whom 4 experienced transaminitis. One patient experienced a grade V CNS hemorrhage. Conclusions: This is the largest prospective VHL disease specific therapeutic study performed to date. Pazopanib resulted in significant and sustained disease control for the majority of VHL patients enrolled on the study, with an acceptable safety profile. This agent may be considered as an alternative to surgical intervention in patients with VHL disease. Clinical trial information: NCT01436227.
Up regulation of CYP1B1 is an early event in gastro-oesophageal reflux mediated oesophageal injury
Authors: AAC Menezes, P Bonde, C Swarbrick, A Knipe, Z Bell, SR McKeown, T Robson, K Khosraviani, DG Hirst, FC Campbell, JA McGuigan
Journal: Endoscopy (2005)

Background: Cytochrome P450 1B1 (CYP1B1) catalyzes activation of various carcinogens and has been implicated in early carcinogenesis in various epithelial cancers. Gastro-oesophageal reflux can potentiate malignant changes in oesophageal mucosa and it is hypothesized that CYP1B1 is up-regulated in the presence of gastro-oesophageal reflux.
Tube Feeding in Patients With Advanced Dementia
Authors: Bruce E. Robinson
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Encollage des fistules anales par voie transpérinéale sous contrôle échoendoscopique
Authors: M Barthet, M El Farisi, M Gasmi, V Vitton, A Desjeux, JC Grimaud
Journal: Endoscopy (2006)

Le traitement de fistules périnéales par encollage est une méthode en cours d'évaluation qui semble prometteuse. Il existe plusieurs voies d'abord pour réaliser ce traitement: la voie chirurgicale à ciel ouvert, l'injection sous contrôle écho endoscopique, et enfin par voie transpérinéale sous contrôle endosonographique.
BAFF and CD4 T-Cells Are Major Survival Factors for Splenic Plasma Cells in B Cell Depletion Context: Implications for Autoimmune Diseases
Authors: Lan-Huong Thai, Ailsa Robbins, Simon Le Gallou, Nicolas Cagnard, Jean-Claude Weill, Claude-Agnès Reynaud, Matthieu Mahevas
Journal: Blood (2016)
Correlation of plasma PD-L1 detectability with age in glioma patients.
Authors: Anna Sophie Berghoff, Sahra Pajenda, Ayseguel Ilhan-Mutlu, Georg Widhalm, Karin Dieckmann, Johannes A. Hainfellner, Ludwig Wagner, Christoph Zielinski, Christine Marosi, Matthias Preusser
Journal: Journal of Clinical Oncology (2015)

e13039 Background: Immunotherapies targeting the programmed cell death (PD1) / programmed cell death ligand 1 (PD-L1) axis are promising new agents for the treatment of cancer including glioma. We aimed to investigate soluble PD-L1 in the blood circulation of glioma patients, as this protein may serve as clinical biomarker for therapeutic response to specific inhibitors. Methods: We collected EDTA plasma from peripheral veins of 16 low-grade glioma (LGG) and 68 high-grade glioma (HGG) patients. In each plasma sample, we analyzed the concentration of soluble PD-L1 using a sandwich ELISA using a rabbit polyclonal anti-PDL1/CD274 antibody (Millipore ABF 133) as capture reagent and a non-commercial PD-L1 monoclonal antibody (clone 5H1) as detection antibody. Recombinant PD-L1 serial dilutions were included as standard reference in each analysis. The lower limit of detectability of plasma PD-L1 concentration was 50 pg/ml. Results: PD-L1 in the plasma was detectable in 6/16 (37.5%) LGG patients (median 1232 pg/ml; range 230-16811 pg/ml) and 36/68 (52.9%) HGG patients (median 411 pg/ml; range 55-42105 pg/ml). There was no statistically significant difference in detectability or concentration of circulating PD-L1 between LGG and HGG (p>0.05, Chi Square and Mann Whitney U test). Glioma patients with detectable plasma PD-L1 concentrations were significantly younger than patients without detectable plasma PD-L1 concentrations (50 vs. 61 years; p=0.006; Mann Whitney U test). Conclusions: We established a novel ELISA assay for analysis of soluble PD-L1 in human plasma samples. Using this assay, we demonstrate that circulating PD-L1 is detectable in a considerable fraction of glioma patients and correlates with patient age. Our data may stimulate further studies to determine the biological and potential clinical relevance of circulating PD-L1 in glioma patients.
Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography
Authors: Haojun Chen, Xiao Tong, Lixin Lang, Orit Jacobson, Bryant C. Yung, Xiangyu Yang, Ruiliang Bai, Dale O. Kiesewetter, Ying Ma, Hua Wu, Gang Niu, Xiaoyuan Chen
Journal: Theranostics (2017)

Purpose: Evans Blue (EB) is an azo dye that binds quantitatively with serum albumin. With an albumin binding, NOTA conjugated truncated Evan's blue (NEB) dye derived PET tracer, we aimed to establish a strategy for evaluating vascular permeability in malignant tumors via non-invasive PET. Experimental design: Sixty-minute dynamic PET using [18F]FAl-NEB was performed in three xenograft tumor models including INS-1 rat insulinoma, UM-SCC-22B human head and neck carcinoma and U-87 MG human glioblastoma. Tumor vascular permeability was quantified by the difference of the slopes between tumor and blood time-activity curve (TACs, expressed as Ps ). The method was further substantiated by EB extraction and colorimetric assay and correlates with that calculated from dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The changes in tumor vasculature at different time points were assessed with NEB PET in U-87 MG and UM-SCC-22B tumor models after treatment with bevacizumab or doxorubicin. Result: The Ps values calculated from tumor and blood TACs from multiple time-point static images are consistent with those from dynamic images. Moreover, the Ps showed a positive and significant correlation with extracted EB concentration and KPS-MRI generated from DCE-MRI, which further confirmed the soundness of this methodology. The antiangiogenic effect of bevacizumab could be revealed by NEB PET in U-87 MG tumors as early as 8 hrs after therapy, demonstrated by a substantial decrease of Ps. On the contrary, there was no significant change of Ps in bevacizumab treated UM-SCC-22B tumors, compared with control group. However, the significant changes of Ps were overestimated in doxorubicin treated UM-SCC-22B tumors. Conclusions: We successfully developed a relatively convenient and novel strategy to evaluate vascular permeability and blood volume using NEB PET. This method will be advantageous in evaluating vascular permeability, promoting drug delivery, and monitoring tumor response to therapeutics that affect tumor angiogenesis.
Combien de ponctions sous échoendoscopie faut-il faire avant d'écarter l'origine néoplasique d'une masse pancreatique?
Authors: M Gasmi, S Brardjanian, S Hamila, E Mendoza, S Garcia, JP Dalbies, JC Grimaud, M Barthet
Journal: Endoscopy (2005)

La ponction sous échoendoscopie de masse pancréatique solide est souvent limitée par sa valeur prédictive négative qui est proche, dans la littérature, de 50%. Le but de ce travail prospectif était de connaître la fréquence et la cause des faux négatifs rencontrés au cours des ponctions de masse solide pancréatique.
Guillain-Barré syndrome and arboviral infection in Brazil
Authors: Tatjana Souza Lima Keesen, Roque P de Almeida, Bruna Macêdo Gois, Rephany Fonseca Peixoto, Anna Stella Cysneiros Pachá, Fernanda Carolina Fernandes Vieira, Marcelo Paixão, Rodrigo Cazzaniga, Rosemary J Boyton, Daniel M Altmann
Journal: The Lancet Infectious Diseases (2017)
Tidal changes on CT and progression of ARDS
Authors: Maurizio Cereda, Yi Xin, Hooman Hamedani, Giacomo Bellani, Stephen Kadlecek, Justin Clapp, Luca Guerra, Natalie Meeder, Jennia Rajaei, Nicholas J Tustison, James C Gee, Brian P Kavanagh, Rahim R Rizi
Journal: Thorax (2017)

Uncertain prediction of outcome in acute respiratory distress syndrome (ARDS) impedes individual patient management and clinical trial design.To develop a radiological metric of injurious inflation derived from matched inspiratory and expiratory CT scans, calibrate it in a model of experimental lung injury, and test it in patients with ARDS.73 anaesthetised rats (acid aspiration model) were ventilated (protective or non-protective) for up to 4 hours to generate a spectrum of lung injury. CT was performed (inspiratory and expiratory) at baseline each hour, paired inspiratory and expiratory images were superimposed and voxels tracked in sequential scans. In nine patients with ARDS, paired inspiratory and expiratory CT scans from the first intensive care unit week were analysed.In experimental studies, regions of lung with unstable inflation (ie, partial or reversible airspace filling reflecting local strain) were the areas in which subsequent progression of injury was greatest in terms of progressive infiltrates (R=0.77) and impaired compliance (R=0.67, p<0.01). In patients with ARDS, a threshold fraction of tissue with unstable inflation was apparent: >28% in all patients who died and ≤28% in all who survived, whereas segregation of survivors versus non-survivors was not possible based on oxygenation or lung mechanics.A single set of superimposed inspiratory-expiratory CT scans may predict progression of lung injury and outcome in ARDS; if these preliminary results are validated, this could facilitate clinical trial recruitment and individualised care.
Раціональна ІПП-терапія: ризики та переваги тривалого застосування інгібіторів протонної помпи в оновлених рекомендаціях експертів Американської гастроентерологічної асоціації
Authors: Yu.M. Stepanov
Journal: GASTROENTEROLOGY (2017)

У статті представлені оновлені практичні рекомендації Американської гастроентерологічної асоціації (AGA) щодо тривалого застосування інгібіторів протонної помпи (ІПП). Десять рекомендацій, сформульовані групою авторитетних американських гастроентерологів на чолі з D.E. Freedberg, засновані на великому огляді й аналізі якості доказів абсолютних і відносних ризиків і переваг ІПП-терапії, наведених в найбільш значущих сучасних дослідженнях, і покликані допомогти клініцистам вибрати найбільш безпечні та ефективні методи лікування пацієнтів із застосуванням ІПП.
Short breast MRI screening trial in women at high-risk for breast cancer.
Authors: Marion Scoggins, Basak Dogan, Jingfei Ma, Wei Wei, Jong Bum Song, Rosalind P Candelaria, Jennifer Keating Litton, Banu Arun
Journal: Journal of Clinical Oncology (2017)

e13049 Background: The American Cancer Society (ACS) recommends yearly breast MRI (BMRI) in addition to mammography for women with high breast cancer risk. However, standard BMRI protocols have a long acquisition time and consequently long interpretation time, which can reduce patient compliance and drive MRI cost. Therefore, we aimed to evaluate an American College of Radiology (ACR)-compliant short BMRI (SBMRI) protocol vis-à-vis compared with standard of care BMRI (SOC-BMRI) obtained in the same high-risk patient. To the best of our knowledge, a prospective study comparing both techniques does not exist. Our primary endpoint is to compare positive predictive value and cancer detection rate. Secondary endpoint is measuring and comparing patient experience between two techniques. As the study and accrual is ongoing and primary endpoint will be evaluated at the completion of accrual in a blinded fashion, here we report characteristics of patients who participated so far. Methods: This is a prospective HIPAA compliant and IRB approved trial. High risk women undergoing SOC-BMRI based on ACS screening guidelines signed an informed consent form to undergo an additional SBMRI within 7 days of the SOC-BMRI. Accrual target goal is 200 patients to give statistical power to estimate sensitivity and 95% confidence interval, with 10% or less expected to have breast cancer. Results: A total of 59 women were enrolled so far. Median age is 53 (range 26-72). Nine (15.3%) had BRCA1 or BRCA2 pathogenic mutations; 6 (10.2%) variant of uncertain significance (VUS). One (1.7%) had CDH1 pathogenic mutation, one (1.7%) had VUS in PALB2. Personal history of breast cancer was present in 2 (3.4%), atypical hyperplasia in 9 (15.3%), LCIS in 3 (5.1%), family history (FH) of breast cancer in 55 (93.2%). Hormone replacement therapy use was current in 2 (3.4%), past in 10 (16.9%). Use of raloxifene, tamoxifen, or aromatase inhibitors was current in 8 (13.6%), past in 5 (8.5%). Conclusions: In this BMRI study comparing SOC-BMRI versus SBMRI, the distribution of breast cancer risk factors reflects our routine cohort, with most patients screened based on FH of breast cancer. Clinical trial information: Primary ID 2015-0243 Secondary IDs NCI-2015-02031 Clinicaltrials.gov ID NCT02590458.
Book: The Medical Society of London 1773-2003
Authors: M D O'Brien
Journal: BMJ (2004)

The Medical Society of London is the oldest extant medical society in England and possibly in the world, the only one of numerous medical societies formed in the 18th century to survive. It was founded in 1773 by John Coakley Lettsom, a Quaker born on Tortola in the British Virgin Islands, who came to England at the age of 6 for a Quaker education in Lancashire, where the preacher Samuel Fothergill became his guardian.​guardian.




Figure 1



Penelope Hunting

The Medical Society of London, £55 plus postage, pp 344 129 illustrations (30 in colour) Available from 11 Chandos Street, London W1G 9EB ISBN 0905082 35 00

Rating: ★★★★




At the age of 22 Lettsom was taken on by Samuel's brother, Dr John Fothergill, a well established London physician. He studied at St Thomas' Hospital and in Edinburgh, and in 1769 he submitted his MD thesis at Leiden University. He was licensed to practise by the Royal College of Physicians in 1770 and elected a fellow of the Royal Society in 1773. Lettsom also started the dispensary movement with the opening of the General Dispensary in 1770, and he founded the Royal Sea Bathing Hospital at Margate (1796-1996).

The purpose of the Medical Society of London was to provide a meeting place and forum for physicians, surgeons, and apothecaries to present papers and patients and to discuss matters of interest. The first premises were in Crane Court off Fleet Street and close to the Royal Society. In 1787 Lettsom bought a house for the society in Bolt Court, opposite Samuel Johnson's house. In 1850 the society moved to Hanover Square after merger with the West-minster Medical Society. Finally, in 1873 the society acquired its present home in Chandos Street.

The society quickly reached prominence on the London medical scene. By 1789 there were 250 fellows with 50 overseas corresponding members from all over the world, including from St Petersburg, Jamaica, Milan, and Philadelphia. Two of the society's members signed the American Declaration of Independence.

The society has been involved with most of the advances and controversies in medicine over the past two centuries. Penelope Hunting has covered not only the chronological history of the society, with its trials and tribulations, but also the many contributions of its fellows. Of particular interest are the book's appendices, which list the society's presidents from 1773, the orators from 1774, the Fothergill medallists from 1787, and the Lettsomian lecturers from 1851. These include many of the most illustrious names in British medicine of the past 230 years.
Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response
Authors: Robyn M. Emanuel, Amylou Constance Dueck, Holly Lynn Geyer, Jean-Jacques Kiladjian, Stephanie Slot, Sonja Zweegman, Peter te Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Dolores Hernandez, Ana Kerguelen Fuentes, Heike L. Pahl, Frank Stegelmann, Konstanze Doehner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N Harrison, Deepti H Radia, Pablo J. Muxi, Norman I Maldonado, Carlos Besses, Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria Ferrari, Martin Griesshammer, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Robert Peter Gale, Ayalew Tefferi, Ruben A. Mesa
Journal: Blood (2013)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Authors: Ajai Chari, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jonathan L. Kaufman, Jainulabdeen J. Ifthikharuddin, Brendan M. Weiss, Amrita Krishnan, Suzanne Lentzsch, Raymond Comenzo, Jianping Wang, Kerri Nottage, Christopher Chiu, Nushmia Z. Khokhar, Tahamtan Ahmadi, Sagar Lonial
Journal: Blood (2017)